| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
In epicutaneously sensitized mice, suppression of skin inflammation in the antigen-administered site alleviated oral challenge-induced symptoms. The changes in mRNA expression profiles in the skin and intestine suggested that suppression of basophil activation and type 2 cytokine expression in the skin and mast cell activation in the intestine was involved in the alleviation of the symptoms.
Application of OVA-encapsulated nanoparticles, which were made by poly(lactide-co-glycolide), increased serum levels of OVA-specific IgG. Epicutaneous immunotherapy with these nanoparticles tended to suppress symptoms induced by oral challenge of OVA. However, butyrate ester-encapsulated nanoparticles did not show any adjuvant effects.
|
